Skip to main content
EMV CAPITAL PLC logo

EMV CAPITAL PLC — Investor Relations & Filings

Ticker · EMVC ISIN · GB00BN4R5Q82 LEI · 213800N5WD46G1Y7I458 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2025-03-27 Earnings Release
Country GB United Kingdom
Listing IL EMVC

About EMV CAPITAL PLC

https://www.emvcapital.com/

EMV Capital PLC is a venture capital investment group specializing in deep tech and life sciences. The firm identifies, invests in, and builds high-growth, IP-rich companies with an international portfolio, focusing on sectors including industrial technology, healthcare, and sustainability. It employs a capital-efficient investment strategy that combines syndicated investments, direct balance sheet funding, and managed funds to support companies from their early stages through to successful exit. EMV Capital engages in proactive portfolio management, often taking board positions and working closely with company leadership. It provides extensive value creation services, including support for fundraising, exit readiness, IP strategy, and corporate collaborations, to drive growth and maximize returns for investors through strategic exits.

Recent filings

Filing Released Lang Actions
PDS: Q4 Results and Clinical Programs Update
Earnings Release Classification · 95% confidence The document is an RNS announcement (indicated by 'RNS Number' and the closing section referencing RNS, LSE, and FCA). The content is an update from EMV Capital plc regarding its portfolio company, PDS Biotech, which reports its 'Full Year 2024 Financial Results' and provides a clinical programs update. Since this is an announcement *about* the results and clinical progress, rather than the full, comprehensive Annual Report (10-K) or a standalone Audit Report (AR), it fits best as an Earnings Release (ER) if it were quarterly, or more generally, a Regulatory Filing (RNS) since it's a broad update disseminated via the RNS system. However, the core content is the reporting of annual financial results and operational updates. Given the structure, which summarizes key financial figures (Net loss, R&D expenses) and operational milestones, it functions as an initial release of annual performance data, which aligns closely with the purpose of an Earnings Release (ER), even though it's an update on a portfolio company. Since the document explicitly states 'PDS Biotech Reports Full Year 2024 Financial Results', and EMV Capital is reporting this news via RNS, the most specific classification for the *type of information* being conveyed is related to earnings/results. If it were just a general operational update without financial figures, RNS would be better. Because it contains detailed financial summaries for the full year, ER is the most appropriate specific code, even though it is distributed via RNS. FY 2024
2025-03-27 English
PDS: VERSATILE-003 Phase 3 Clinical Trial
Regulatory Filings Classification · 98% confidence The document starts with 'RNS Number : 8848Z' and is dated '07 March 2025' with the header 'For immediate release'. It details an announcement from EMV Capital plc regarding an update on its portfolio company, PDS Biotech, specifically the initiation of a Phase 3 clinical trial. This format—a brief, immediate announcement disseminated via the RNS system of the London Stock Exchange—is characteristic of a general regulatory news service release. Since the content is an announcement about clinical trial progress rather than a comprehensive financial report (like 10-K or IR) or a specific management/dividend notice, the most appropriate classification is the general regulatory filing category.
2025-03-07 English
PDS: up to $22mn Registered Direct Offering
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number: 7704Y), which is the news service of the London Stock Exchange and an FCA Primary Information Provider. The content details a significant corporate action involving a portfolio company (PDS Biotech) of the reporting entity (EMV Capital PLC), specifically announcing a 'Registered Direct Offering' (a financing/capital raising event). While it relates to capital, the primary nature of this document is a general regulatory news update disseminated through the official channel (RNS). Since it is a short announcement reporting on an event and directs the reader to the full announcement elsewhere ('A full version of PDS Biotech's announcement can be accessed here: [link]'), it fits the criteria for a general regulatory filing or news release rather than a specific report type like ER or IR. Given the options, RNS (General Regulatory Filings) is the most appropriate classification for a standard LSE news service release that doesn't fit a more specific category like DIV, CAP, or DIRS.
2025-02-27 English
PDS Biotech reaffirms guidance for clinical trial
Regulatory Filings Classification · 98% confidence The document starts with an RNS Number and is dated 05 February 2025, indicating a regulatory announcement format typical of the London Stock Exchange's Regulatory News Service (RNS). The content is an update from EMV Capital plc regarding its portfolio company, PDS Biotech, specifically about reaffirming guidance for initiating a Phase 3 clinical trial. This is not a full financial report (like 10-K or IR), nor is it a specific announcement like a dividend (DIV) or director dealing (DIRS). It is a general corporate update disseminated via the RNS system. Since it is a specific corporate update that doesn't fit the other specialized categories (like ER, CAP, MANG), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2025-02-05 English
ProAxsis: Status Update and Proposed Fundraise
Regulatory Filings Classification · 98% confidence The document is an official announcement released via RNS (Regulatory News Service) on February 3, 2025. It details the financial and operational progress of a portfolio company (ProAxsis Ltd) and announces a proposed fundraising round for that subsidiary. The content focuses on revenue growth, cost reduction, partnership updates, and a planned equity issue for capital raising. This structure—an update on a portfolio company's performance and financing activities released through a regulatory news wire—is characteristic of a general regulatory announcement rather than a specific statutory report like a 10-K or IR. Since it is a general regulatory announcement disseminated via RNS and does not fit the specific definitions for ER, DIV, CAP, or MANG (though it touches on fundraising), the most appropriate general classification for a non-standard, timely regulatory update distributed via the LSE's service is RNS.
2025-02-03 English
TR-1
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is filed via RNS (RNS Number : 2976S). This form is used to report changes in significant share ownership, specifically detailing the percentage of voting rights held by an individual (Dr Ilian P Iliev) and an associated entity (Futura Messis Group Limited), crossing a notification threshold. This directly corresponds to the definition of a Major Shareholding Notification.
2025-01-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.